Benzinga | Dec 7, 2021 07:16AM EST

Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor

* Inventiva (NASDAQ:IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity.

* The assessment of lanifibranor on cardiac repolarization was conducted under FDA in Phase 1 double-blind clinical trial to be included in the marketing application package of lanifibranor for the treatment of NASH.

* The trial enrolled 217 healthy subjects who were randomized into four arms.

* The primary electrocardiogram (ECG) endpoint was monitored during the first 24hrs and on the last day of treatment.

* Lanifibranor administered at the anticipated maximal therapeutic dose of 1200mg/day and the supra-therapeutic dose of 2400mg/day had no impact on QT/QTc interval.

* Lanifibranor was well tolerated at both dose levels.

* Related: Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022.

* Price Action: IVA shares closed at $13.61 on Monday.